In 93.2% of the adolescent volunteers who participated in the clinical trials of the Sputnik-M vaccine intended for children aged 12-17 years, cellular immunity was developed, according to what is mentioned in the instructions of the preparation.
It is noted that in a study of the humoral immune response (Humoral Immune Response) the sera of the volunteers were analyzed for antibodies on the 42nd day after the start of the vaccination: “The rate of seroconversion (the time during which a person develops antibodies) was 100%”. It is noted that the protective titer of antibodies as well as the duration of protection are currently unknown.
The instructions for the preparation detail the contraindications for vaccination with Sputnik M, such as severe allergic reactions, acute infectious and non-infectious diseases and the aggravation of chronic diseases, hypersensitivity to any component of the vaccine. Also, Sputnik M should be used with caution in cases of chronic diseases of the liver and kidneys, as well as the endocrine system.
The Russian Ministry of Health has registered a vaccine against coronavirus Sputnik M, which will be used to prevent infection in adolescents aged 12 to 17 years. The vaccine will be given in two doses every 21 days. The Ministry of Health points out that the vaccination of adolescents aged 12 to 15 years will be done only with the consent of parents or guardians, while from 15 years and over with their own written voluntary consent.
.
